Tepotinib, sold under the brand name Tepmetko, is an anti-cancer medication used for the treatment of adults with non-small cell lung cancer (NSCLC)....
14 KB (935 words) - 03:22, 19 February 2024
overactive MET, which can be inhibited with MET inhibitors capmatinib or tepotinib. Targeted therapies are also available for some cancers with rare mutations...
90 KB (9,784 words) - 07:53, 10 October 2024
Pexidartinib L01EX17 Capmatinib L01EX18 Avapritinib L01EX19 Ripretinib L01EX21 Tepotinib L01EX22 Selpercatinib L01EX23 Pralsetinib L01EX24 Surufatinib L01EX25...
12 KB (877 words) - 15:36, 25 January 2024
Nintedanib Odronextamab Pazopanib Pemigatinib Pexidartinib Quizartinib Regorafenib Ripretinib Sorafenib Sunitinib Tebentafusp Tepotinib Vandetanib Venetoclax...
12 KB (821 words) - 02:57, 12 October 2024
Nintedanib Odronextamab Pazopanib Pemigatinib Pexidartinib Quizartinib Regorafenib Ripretinib Sorafenib Sunitinib Tebentafusp Tepotinib Vandetanib Venetoclax...
12 KB (758 words) - 23:46, 14 March 2024
approval to treat kidney cancer. Tepotinib, (MSC 2156119J), has reported phase II clinical trial results on lung cancer. Tepotinib was granted breakthrough therapy...
32 KB (3,542 words) - 19:34, 2 July 2024